A week after UCB bought Ra to get hold of its complement inhibitor, Alexion takes out Achillion for much the same reason.
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.
Others hoping to get FDA approvals include Sage Therapeutics and Novartis, but hopes look dimmer for Lexicon and Sanofi.
Promising mid-stage data in a third indication for efgartigimod have given the Belgian company another boost.
Data show that prices hardly budged in the first few months of 2017.